PRESS RELEASE ARCHIVES FROM SEND2PRESS® NEWSWIRE
NOTICE: THIS IS ARCHIVAL CONTENT AND LIKELY OUT OF DATE.
Article Editor: Carly Zander
First American Gains Therapeutic Benefit From REXIN-G, The Leading Tumor-Targeted Gene Therapy Vector For Pancreatic Cancer
LOS ANGELES, Calif. - May 13, 2004 /Send2Press Newswire/ -- Epeius Biotechnologies
Corporation (www.epeiusbiotech.com), today announced that the first American with
advanced pancreatic cancer has responded favorably to Rexin-G, the leading tumor-
targeted injectable gene therapy vector for metastatic cancer. While Epeius
Biotechnologies Corporation has recently gained FDA approval to open Phase I/II
clinical trials in the United States, the first American patient opted to travel to
Manila, Philippines, to receive the gene therapy intervention there, where the first
clinical studies using Rexin-G for pancreatic cancer were conducted (International
Journal of Oncology, January, 2004).
Over a one-month period, Rexin-G induced a
progressive reduction in the size of his pancreatic tumor, and disappearance or
shrinkage of his liver tumors without serious side effects.
The landmark clinical trial in cancer gene therapy was conducted by Drs. Conrado
Lorenzo III and Gerardo H. Cornelio in a world-class tertiary care hospital in Manila.
The clinical trials using Rexin-G for pancreatic cancer and other solid tumors in
Manila is the result of a global initiative of Drs. Frederick L. Hall and Erlinda M.
Gordon, founders of Epeius Biotechnologies Corporation to bring this targeted cancer
intervention to the world. Dr. Gordon, an Asian-American physician/ scientist was
recently awarded a plaque of recognition and a proclamation for her contributions in
the field of biotechnology by the City of Los Angeles Mayor (James K. Hahn) and
Rexin-G gained U.S. FDA orphan drug approval for pancreatic cancer in the
Fall of 2003, providing further product validation and exclusivity in the marketplace
for years to come.
In a statement to the press, Dr. Hall, President and CEO of Epeius Biotechnologies
remarked that, "The realization that Rexin-G works well in Americans too could
catalyze the financial support needed to rapidly expand the clinical trials in the
However, when questions about curing cancer inevitably arose, Dr. Hall emphasized
caution: "We know that the implications of the TDS [targeted delivery system]
technology are profound. However, while the targeting technology is indeed effective
in delivering cancer-killing genes to metastatic tumors, and we are accumulating
clinical evidence that Rexin-G is effective in pancreatic cancer, discussions about a
'cure' is premature, as this conclusion can only be made after extensive critical
analysis of the results of a large number of clinical trials has been performed."
About Epeius Biotechnologies
Epeius Biotechnologies Corporation is a privately held biopharmaceutical company whose
mission is to develop and commercialize the first truly effective Targeted Delivery
System (TDS) that can be injected directly into a vein to deliver genes and molecular
therapeutics preferentially to cancerous tumors that have spread throughout the body
(metastatic cancer), without eliciting systemic side effects or organ damage.
lead product, Rexin-G, is the first tumor-targeted injectable gene therapy vector that
has been approved by both the U.S. FDA and the Philippine BFAD (FDA counterpart) for
use in Phase I/II clinical trials for pancreatic and colon cancer.
Previous News from Epeius Biotechnologies Corporation
DISCLAIMER: the above article is believed accurate but not guaranteed, and is based on business news supplied by the organization mentioned and/or quoted in the story. The organization providing the news to Send2Press is solely responsible for its accuracy. Financial/Stock news may contain forward looking statements and public companies should be thoroughly researched before considering material investment. Neotrope/Send2Press makes no claims of accuracy or suitability for any purpose. Any opinions expressed by representatives of company(s) mentioned in news item are solely those of the person indicated, and do not reflect any opinion or policy of Neotrope/Send2Press. Your use of any information contained herein is done solely at your own risk, and you are fully responsible for using any information herein, or on sites mentioned or linked to in the article. All trademarks acknowledged.
USE OF THE ABOVE NEWS ARTICLE
Article is Copr. © 2004 Neotrope/Send2Press. Reproduction of this news article in any form requires written authorization. You may freely link to this article.